Detalles de la búsqueda
1.
Immunogenicity, Reactogenicity, and Safety of AS01E-adjuvanted RSV Prefusion F Protein-based Candidate Vaccine (RSVPreF3 OA) When Co-administered With a Seasonal Quadrivalent Influenza Vaccine in Older Adults: Results of a Phase 3, Open-Label, Randomized Controlled Trial.
Clin Infect Dis
; 2024 Jan 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-38189778
2.
Impact of maternal diphtheria-tetanus-acellular pertussis vaccination on pertussis booster immune responses in toddlers: Follow-up of a randomized trial.
Vaccine
; 39(11): 1598-1608, 2021 03 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-33612341
3.
Rapid, enhanced, and persistent protection of patients with renal insufficiency by AS02(V)-adjuvanted hepatitis B vaccine.
Kidney Int
; 77(3): 247-55, 2010 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19940840
4.
Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study.
Hum Vaccin Immunother
; 16(9): 2265-2273, 2020 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32048889
5.
Impact of tetanus-diphtheria-acellular pertussis immunization during pregnancy on subsequent infant immunization seroresponses: follow-up from a large randomized placebo-controlled trial.
Vaccine
; 38(8): 2105-2114, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776027
6.
Immunogenicity, transplacental transfer of pertussis antibodies and safety following pertussis immunization during pregnancy: Evidence from a randomized, placebo-controlled trial.
Vaccine
; 38(8): 2095-2104, 2020 02 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-31776029
7.
Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults.
Vaccine
; 36(42): 6325-6333, 2018 10 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-30197282
8.
Corrigendum to 'Antibody persistence and safety and immunogenicity of a second booster dose nine years after a first booster vaccination with a reduced antigen diphtheria-tetanus-acellular pertussis vaccine (Tdap) in adults'. [Vaccine 36 (2018) 6325-6333].
Vaccine
; 38(12): 2746-2747, 2020 Mar 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-32061383
9.
Immunogenicity and safety of an investigational AS02(v)-adjuvanted hepatitis B vaccine in patients with renal insufficiency who failed to respond or to maintain antibody levels after prior vaccination: results of two open, randomized, comparative trials.
Vaccine
; 29(6): 1159-66, 2011 Feb 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-21167859
Resultados
1 -
9
de 9
1
Próxima >
>>